Hematological cancers also seem to benefit from CLK2 inhibition, although CLK2 or MYC did not sensitize these cells to T‐025, thus indicating that alternative mechanisms account for such effects. The gene discussed is CLK2; the disease is hematopoietic and lymphoid cell neoplasm.